Prognostic Value of BIRC5 in Lung Adenocarcinoma Lacking EGFR, KRAS, and ALK Mutations by Integrated Bioinformatics Analysis

Figure 5

Associations between BIRC5 and survival times. OS (a) and RFS (b) in triple-negative (TN) lung adenocarcinomas based on TCGA database. OS (c), FPS (d), and PPS (e) in lung adenocarcinomas (LAD) based on the Kaplan-Meier plotter database. The red lines represent patients with high BIRC5 expression, and the blue and black lines represent patients with a low BIRC5 expression.

(a)

(b)

(c)

(d)

(e)